BiotechTube

Gemcitabine + Cisplatin + Sunitinib Malate

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transitional Cell Carcinoma of the Bladder

Conditions

Transitional Cell Carcinoma of the Bladder

Trial Timeline

Mar 1, 2009 → Apr 1, 2011

NCT ID
NCT00859339

About Gemcitabine + Cisplatin + Sunitinib Malate

Gemcitabine + Cisplatin + Sunitinib Malate is a phase 2 stage product being developed by Pfizer for Transitional Cell Carcinoma of the Bladder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00859339. Target conditions include Transitional Cell Carcinoma of the Bladder.

What happened to similar drugs?

0 of 9 similar drugs in Transitional Cell Carcinoma of the Bladder were approved

Approved (0) Terminated (3) Active (6)
🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3
❌AtezolizumabRochePhase 3
🔄vinflunine and best supportive careBristol Myers SquibbPhase 3
🔄padeliporfin VTPICON plc.Phase 3
🔄UGN-101 instillationsUroGen PharmaPhase 3
🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3
❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00859339Phase 2Terminated

Competing Products

20 competing products in Transitional Cell Carcinoma of the Bladder

See all competitors
ProductCompanyStageHype Score
Enfortumab vedotinAstellas PharmaPhase 2
35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabineAstellas PharmaPhase 1/2
36
Pemetrexed + Gemcitabine + PlatinolEli LillyPhase 1/2
32
Vepugratinib + EV + PembrolizumabEli LillyPhase 3
47
durvalumab and tremelimumabAstraZenecaPhase 2
35
Docetaxel + vandetanib + PlaceboAstraZenecaPhase 2
35
MK-3475 and BCGMerckPhase 2
42
PembrolizumabMerckPhase 2
31
Everolimus + Everolimus + PaclitaxelNovartisPhase 2
27
BuparlisibNovartisPhase 2
35
BEZ235NovartisPhase 2
27
AtezolizumabRochePhase 3
32
Nivolumab/IpilimumabBristol Myers SquibbPhase 2
31
vinflunine and best supportive careBristol Myers SquibbPhase 3
40
vinflunineBristol Myers SquibbPhase 2
35
DasatinibBristol Myers SquibbPre-clinical
26
Docetaxel + OxaliplatinSanofiPhase 2
35
CabazitaxelSanofiPhase 2/3
38
Rogaratinib (BAY1163877) + ChemotherapyBayerPhase 2/3
35
CG0070 Adenovirus VectorCG OncologyPhase 2/3
27